Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aryl hydrocarbon receptor repressor (AHRR) is a transcription factor and repressor protein that regulates cellular responses to environmental chemicals, particularly dioxins. It functions by competing with the aryl hydrocarbon receptor (AHR) for binding to ARNT (aryl hydrocarbon receptor nuclear translocator), inhibiting the activation of AHR target genes and providing a negative feedback loop in AHR signaling. AHRR is ubiquitously expressed in adult tissues but is low in fetal tissues, can act as a tumor suppressor, and its gene encodes a protein with both bHLH and PAS domains. Variants and changes in expression of AHRR have been linked to cancer risk, inflammation, toxicological responses, and potentially endometriosis. There are currently no approved drugs that directly target AHRR, although xenobiotic chemicals such as dioxins interact with the pathway AHRR regulates[1][2][3][4][6].
Competitive inhibition of ARNT binding to AHR (prevents formation of active AHR-ARNT heterodimer, suppresses gene transcription); Transcriptional repression via negative feedback in the AHR signaling pathway
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aryl hydrocarbon receptor repressor (AHRR).